NASDAQ$PHVS
Pharvaris NV · Q1 2026 earnings
Q1 2026 earnings · · Before market open · Investor relations
Briefing
Pharvaris Q1 2026: net loss narrows to €39.2M as CHAPTER-3 topline data and NDA submission loom
Pharvaris N.V. reported Q1 2026 financial results for the three months ended March 31, 2026, as a late-stage biopharmaceutical company advancing oral deucrictibant for bradykinin-mediated angioedema. The pre-revenue company posted a loss of €39.2 million, or €(0.60) basic and diluted loss per share, improved from a €46.3 million loss, or €(0.85) per share, in Q1 2025. Research and development expenses were €30.2 million versus €30.9 million a year ago, while general and administrative expenses rose to €14.1 million from €11.3 million as commercial infrastructure build-out accelerated. Cash and cash equivalents were €247 million at March 31; a subsequent $132 million underwritten offering extended the expected cash runway into 2028. Key pipeline milestones include CHAPTER-3 topline data expected in Q3 2026, on-track NDA submission for deucrictibant IR in 1H 2026, and ongoing enrollment in the CREAATE study for AAE-C1INH.
- Q1 loss narrowed to €39.2M, or €(0.60) per share, from €46.3M, or €(0.85) per share, in Q1 2025.
- R&D expenses were €30.2M; G&A rose to €14.1M as the company builds U.S. commercial infrastructure.
- Cash and equivalents were €247M at quarter end; a subsequent $132M offering extends runway into 2028.
- CHAPTER-3 Phase 3 topline data for deucrictibant XR prophylaxis expected in Q3 2026.
- NDA submission for deucrictibant IR on-demand treatment remains on track for 1H 2026.
Headline financials
Revenue & EPS history
Pharvaris · Revenue · Quarterly
€0
Forward guidance
Pharvaris expects CHAPTER-3 topline data in Q3 2026, NDA submission for deucrictibant IR in 1H 2026, and continued enrollment in CREAATE. Following a $132M offering, management expects cash runway into 2028.
Tailwinds
- Loss per share improved year over year with disciplined capital allocation.
- Multiple late-stage catalysts approaching in 2026 across HAE and AAE-C1INH programs.
Headwinds
- Pre-revenue company with rising G&A as commercial build-out accelerates.
- Clinical and regulatory timelines remain subject to trial readouts and FDA review.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 13 quarterly earnings reports · overlaid with Q1 2026
+16.7%
Avg return
Earnings day
+16.1%
Avg return
5 days after
+27.4%
Avg return
30 days after
36%
5 / 14 earnings
Positive
+243.4%
Q3 2022
Best reaction
-10.4%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.4% | +1.5% | +7.3% | |
| Q3 2025 | +7.3% | +3.3% | +0.2% | |
| Q4 2024 | -10.4% | -9.2% | +29.0% | |
| Q3 2024 | +3.6% | +5.4% | -7.3% | |
| Q4 2023 | -3.6% | -12.9% | -7.3% | |
| Q3 2023 | +9.3% | +2.7% | +9.9% | |
| Q2 2023 | -3.9% | -1.4% | +11.6% | |
| Q4 2022 | -5.2% | -2.0% | +9.0% | |
| Q3 2022 | +243.4% | +241.4% | +376.1% | |
| Q2 2022 | -2.7% | -2.1% | -46.3% | |
| Q4 2021 | -0.8% | -0.4% | -1.1% | |
| Q3 2021 | -0.2% | -0.8% | -6.8% | |
| Q2 2021 | -2.4% | -1.8% | +18.0% | |
| Q1 2021 | +0.0% | +1.2% | -8.7% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro